As of Feb 21, 2025, the HALO stock has a P/E ratio of 16.5. The calculation is based on the latest EPS of $3.5 and the stock price of $57.75 per share. A decrease of 4.3% has been observed in the PE ratio compared to its average of 17.2 of the past four quarters.
The mean historical PE ratio of Halozyme Therapeutics over the last eight years is 31.45. The current 16.5 price-to-earnings ratio is 48% less than the historical average. Analyzing the last eight years, HALO's PE ratio reached its highest point in the Sep 2020 quarter at 146, with a price of $26.28 and an EPS of $0.18. The Mar 2022 quarter saw the lowest point at 12.95, with a price of $39.88 and an EPS of $3.08.
Maximum annual increase: 173.47% in 2022
Maximum annual decrease: -68.73% in 2021
Year | PE ratio | PE change | Price | EPS |
---|---|---|---|---|
2024 | 13.66 | -21.27% | $47.81 | $3.5 |
2023 | 17.35 | -54.88% | $36.96 | $2.13 |
2022 | 38.45 | 173.47% | $56.9 | $1.48 |
2021 | 14.06 | -68.73% | $40.21 | $2.86 |
2020 | 44.96 | N/A | $42.71 | $0.95 |
2019 | N/A | N/A | $17.73 | -$0.5 |
2018 | N/A | N/A | $14.63 | -$0.56 |
2017 | 44.04 | N/A | $20.26 | $0.46 |
2016 | N/A | N/A | $9.88 | -$0.81 |
2015 | N/A | N/A | $17.33 | -$0.25 |
2014 | N/A | N/A | $9.65 | -$0.56 |
2013 | N/A | N/A | $14.99 | -$0.74 |
2012 | N/A | N/A | $6.71 | -$0.48 |
2011 | N/A | N/A | $9.51 | -$0.19 |
2010 | N/A | N/A | $7.92 | -$0.56 |
Year | PE ratio | PE change | Price | EPS |
---|---|---|---|---|
Dec 2024 | 13.66 | -26.72% | $47.81 | $3.5 |
Sep 2024 | 18.64 | -7.08% | $57.24 | $3.07 |
Jun 2024 | 20.06 | 20.84% | $52.36 | $2.61 |
Mar 2024 | 16.6 | -4.32% | $40.68 | $2.45 |
Dec 2023 | 17.35 | -13.25% | $36.96 | $2.13 |
Sep 2023 | 20 | -3.52% | $38.2 | $1.91 |
Jun 2023 | 20.73 | -27.8% | $36.07 | $1.74 |
Mar 2023 | 28.71 | -25.33% | $38.19 | $1.33 |
Dec 2022 | 38.45 | 47.83% | $56.9 | $1.48 |
Sep 2022 | 26.01 | 53.72% | $39.54 | $1.52 |
Jun 2022 | 16.92 | 30.66% | $44 | $2.6 |
Mar 2022 | 12.95 | -7.89% | $39.88 | $3.08 |
Dec 2021 | 14.06 | 0.57% | $40.21 | $2.86 |
Sep 2021 | 13.98 | -49.2% | $40.68 | $2.91 |
Jun 2021 | 27.52 | -20.78% | $45.41 | $1.65 |
The current PE ratio of HALO is under its 3, 5 and 10-year averages.
HALO's PE ratio is below its peer stocks LLY and JNJ. Halozyme Therapeutics's current PE ratio of 16.5 is less than the average of its peers, which is 52.17.
Stock name | PE ratio | Market cap |
---|---|---|
HALO Halozyme Therapeutics Inc | 16.5 | $7.11B |
JNJ Johnson & Johnson | 27.79 | $390.76B |
PFE Pfizer Inc | 34.61 | $149.04B |
MNKD Mannkind Corp | 72 | $1.59B |
LLY ELI LILLY & Co | 74.29 | $828.4B |
BAX Baxter International Inc | N/A | $17.3B |
As of Feb 21, 2025, HALO stock has a price to earnings ratio of 16.5.
Over the last 3 years, the average PE ratio for HALO stock is 20.84.
Over the last 5 years, the average PE ratio for HALO stock is 29.52.
Over the last eight years, the quarterly PE ratio reached its highest level at 146 in the Sep 2020 quarter.
HALO's current price to earnings ratio is 48% below its 8-year historical average.
To determine the P/E ratio, divide the latest stock price by the TTM earnings per share (EPS). As of today (Feb 21, 2025), Halozyme Therapeutics's share price is $57.75. The company's earnings per share for the trailing twelve months (TTM) ending Dec 2024 is $3.5. Therefore, Halozyme Therapeutics's price to earnings ratio for today is 16.5. PE RATIO(16.5) = STOCK PRICE($57.75) / TTM EPS($3.5)
All PE ratio stats are based on quarterly TTM periods, unless otherwise specified. Data from and Sharadar.